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Restricted Access and Delays to HCV Treatment Among Medicaid Patients in
Louisiana
Abstract
Background: Many people living with chronic Hepatitis C Virus (HCV) have seen delays in accessing
treatment or been denied entirely due to Medicaid restrictions requiring patients to meet certain criteria
prior to receiving approval for medication pre-authorization.
Methods: This study identified a cohort of Medicaid-insured patients with chronic HCV infection within
New Orleans, LA. Patient medical records were reviewed and information regarding HCV care was
gathered. This study sought to determine the degree to which HCV care was delayed for this population
and describe common reasons for prior-authorization denials for direct-acting antiviral (DAA)
medications.
Results: For this population of Medicaid-insured patients with HCV RNA assay-confirmed chronic
infection, the average number of days it took to reach a specialist was three-times greater than the
number of days it took to reach a primary care physician. After attending an appointment with a specialist
to seek HCV care, patients experienced wait periods of an average of 150 days before being deemed
eligible for treatment per Medicaid requirements. After being deemed eligible for treatment, patients
experienced an average wait period of 194.4 days to initiation of treatment, with low fibrosis status being
cited as the most common reason for treatment delay.
Conclusion: This population of Medicaid-insured patients in New Orleans, LA with chronic HCV infection
experienced delays in treatment related to reduced accessibility of a specialist who was eligible to
request DAA prior-authorization. Prior-authorization was most frequently denied based on low fibrosis
status or recent alcohol/drug use.
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ABSTRACT
Background: Many people living with chronic Hepatitis C Virus (HCV) have seen delays
in accessing treatment or been denied entirely due to Medicaid restrictions requiring patients to
meet certain criteria prior to receiving approval for medication pre-authorization.
Methods: This study identified a cohort of Medicaid-insured patients with chronic HCV
infection within New Orleans, LA. Patient medical records were reviewed and information
regarding HCV care was gathered. This study sought to determine the degree to which HCV care
was delayed for this population and describe common reasons for prior-authorization denials for
direct-acting antiviral (DAA) medications.
Results: For this population of Medicaid-insured patients with HCV RNA assay-confirmed
chronic infection, the average number of days it took to reach a specialist was three-times greater
than the number of days it took to reach a primary care physician. After attending an appointment
with a specialist to seek HCV care, patients experienced wait periods of an average of 150 days
before being deemed eligible for treatment per Medicaid requirements. After being deemed
eligible for treatment, patients experienced an average wait period of 194.4 days to initiation of
treatment, with low fibrosis status being cited as the most common reason for treatment delay.
Conclusion: This population of Medicaid-insured patients in New Orleans, LA with
chronic HCV infection experienced delays in treatment related to reduced accessibility of a
specialist who was eligible to request DAA prior-authorization. Prior-authorization was most
frequently denied based on low fibrosis status or recent alcohol/drug use.
Keywords: Health inequities; hepatitis C; Medicaid; direct-acting antiviral
INTRODUCTION
In 2015, an estimated 3.5 million people in the United States were chronically infected
with the hepatitis C virus (HCV), with the potential for underestimation indicating that the true
prevalence could be much greater (Edlin et al., 2015). An important public health implication of
untreated chronic and progressive HCV infection is the potential for further transmission of the
virus. Chronic infection leads to increased morbidity and mortality, including potential cirrhosis,
end-stage liver disease, and hepatocellular carcinoma (Liang et al., 2000). Fortunately, recent
Journal of Health Disparities Research and Practice Volume 12, Issue 1, Spring 2019
http://digitalscholarship.unlv.edu/jhdrp/
Follow on Facebook: Health.Disparities.Journal
Follow on Twitter: @jhdrp

127 Restricted Access and Delays to HCV Treatment Among Medicaid Patients in Louisiana—
Kim and McGonigle
pharmacologic innovations in the form of direct-acting antivirals (DAA) have made safe and
highly effective eradication of HCV possible (Afdhal et al., 2014). A study of Veterans Affairs
patients documented that progression to cirrhosis and a decompensation event in the setting of
HCV infection may occur more quickly than previously thought (Butt et al., 2015). Moreover,
sustained virological response following antiviral treatment has been shown to decrease liverrelated morbidity and all-cause mortality among patients with chronic HCV infection, even those
with advanced hepatic fibrosis (van der Meer et al., 2012). As a result, the current guidelines
recommend treatment of all genotypes of HCV with DAAs (AASLD/IDSA, 2017).
Since their advent in 2013, the US Food and Drug Administration has approved numerous
types of DAAs for the treatment of HCV (FDA, 2017). However, the high costs of DAAs have
caused both private and public insurers in the US to limit access to these medications (Trooskin et
al., 2015). Like other insurers, Medicaid has set specific reimbursement criteria such as
consultation with a specialist, sobriety from alcohol and illicit drugs, and evidence of advanced
fibrosis or cirrhosis (Barua et al., 2015). These Medicaid restrictions vary from state to state (Barua
et al., 2015). Multiple studies have shown the negative impact of these Medicaid restrictions. A
prospective cohort study across four Northeast states showed significantly higher rates of DAA
absolute denial among those insured by Medicaid (46%) compared to those insured by Medicare
(5%) and by commercial insurance (10%) (Re et al., 2016). Another cohort study in Southeast
Michigan yielded similar results (Bourgi, et al., 2016).
From 2015 to May 2018, Louisiana Medicaid required abstinence from illicit substances
and alcohol use for 12 months, one of only two states to do so, with other states ranging from no
requirements to 6 months of abstinence (Barua et al., 2015). Prescribing physicians were required
to provide proof of abstinence with a negative urine drug screen and blood alcohol level within 30
days of initiating treatment in addition to conducting random drug and alcohol screenings every
30 days throughout the course of treatment (Louisiana Department of Health, 2016). At that time,
Louisiana was one of 14 states that only permitted physicians within the specialties of
gastroenterology, hepatology, or infectious disease to request DAA pre-authorization (Barua et al.,
2015). Louisiana Medicaid also required that the patient met criteria for advanced fibrosis or
cirrhosis prior to DAA pre-authorization (Louisiana Department of Health, 2016).
Heterogeneity of Medicaid pre-authorization criteria for DAAs between states has led to
confusion for policy-makers and providers. Anecdotally, providers are well-aware of institutional
and policy barriers to accessing treatment for their patients, though there is a paucity of published
data regarding the impact of Medicaid restrictions and reasons for treatment denial and delay at
the state level. In this study, medical records of Medicaid-insured patients with chronic HCV
infection within New Orleans, LA were reviewed to better understand their clinical course and
evaluate the effects of restrictive Medicaid reimbursement criteria. It was hypothesized that
Louisiana’s restrictive Medicaid reimbursement criteria would create considerable barriers to
treatment and cause delays in treatment for patients medically indicated for DAA treatment.
METHODS
Study patients were selected retrospectively from a pool of patients with chronic HCV
infection within the treatment cascade of “Acacia NOLA,” a student-run HCV screening and
treatment program in New Orleans, LA. Program sites were primarily located at homeless shelters
and substance abuse treatment centers across the city. Patients were initially included if they
screened antibody positive for HCV and were referred for further evaluation and treatment by
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Acacia NOLA between March 1, 2015 (inception of Acacia NOLA) and June 30, 2018 (conclusion
of study period). Included patients were further refined to those who had been scheduled for an
appointment with an HCV specialist after completing the necessary evaluation for referral,
including a quantitative HCV RNA screen.
Primary outcomes were the average number of days to attain each step in the treatment
process, including attending a specialist appointment, completing eligibility for DAA access, and
starting treatment. Secondary outcomes included reasons for DAA eligibility delay and reasons
for pre-authorization denial, as detailed in provider notes. Information about achievement along
the treatment cascade was obtained by reviewing the electronic medical records (EMR) of both a
local federally qualified health center (FQHC) and a local community hospital to which Acacia
NOLA refers its patients. Data gathered from the FQHC included dates of scheduled primary care
physician (PCP) appointments and dates of attended PCP appointments. These dates were used to
calculate average number of days to access a PCP following a positive HCV antibody screen as a
baseline measure of access to physician services. Average time in days to PCP appointments was
compared with average time in days to specialist appointments.
Dates of scheduled viral hepatitis clinic (VHC) appointments with a specialist, dates of
attended VHC appointments, reasons for pre-eligibility delays, reasons for post-eligibility delays,
dates of treatment initiation, and dates of treatment completion were gathered from the local
community hospital EMR. The dates were used to calculate the number of days between each step
of the treatment cascade required by Medicaid to describe a care timeline for this patient
population. Patients who completed a treatment eligibility workup with a PCP comprised the
“VHC eligible” cohort, while those attending at least one VHC appointment were defined as “VHC
attained.” Pre-eligibility delays were defined as the amount of time in days between first VHC
appointment and being deemed eligible to apply to Medicaid for treatment. Patients whose DAA
application to Medicaid was submitted during their first clinic appointment served as a baseline.
Post-eligibility delays were defined as the amount of time in days between being deemed eligible
to apply to Medicaid for treatment by a specialist and treatment initiation, with 21 days from
eligibility to initiation serving as a baseline. Reasons for pre- and post-eligibility delays as
described by providers were documented. Patient demographics and self-described characteristics
were extracted from Acacia NOLA’s preliminary intake survey of clients during initial antibody
screening session. The study was approved by the Tulane University Institutional Review Board.
RESULTS
Demographics and self-reported characteristics
Between March 1, 2015 and June 30, 2018, 99 patients completed eligibility requirements
for HCV specialist referral and were included in this study. These patients were confirmed to be
living with chronic HCV infection by quantitative RNA assay and were scheduled for a VHC
appointment. Of this group, 38 (38.4%) attended at least one VHC appointment (VHC attained)
over the study period while the remaining 61 (61.7%) did not (VHC eligible). Patient
demographics were described by VHC attainment status (Table 1). Self-reported prior experience
with healthcare, perceived barriers to accessing care, and risk factors were assessed for differences
between ‘VHC eligible’ and ‘VHC attained’ sub-groups (Table 2). There was a high awareness of
HCV status at intake, with 53.5% of clients previously knowing their status. Just 17% of patients
reported having a personal PCP upon intake, though 88% of patients reported having tried to access
healthcare previously. Patients attending at least one VHC appointment were less likely to report
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distrust of the healthcare system and more likely to perceive incarceration as a barrier to accessing
healthcare. Otherwise, no significant differences exist between subgroups.
Medicaid application
submitted

No tx access delays
(n= 3)

Did not attend VHC
(n=61)
Eligible for
specialist care
(n=99)

Tx access delays
(n = 12)

No eligibility delays
(n = 15)

Attended at least 1
VHC appt
(n = 38)

No tx access delays
(n = 3)
Eligibility delays
(n = 23)

Completed
eligibility (n = 9)
Tx access delays
(n=6)

Figure 1. Attainment and associated delays along the HCV treatment cascade.
a

Tx = treatment

Table 1. Demographics
Testing site type

VHC Eligible

VHC Attained

Total
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n

%

n

%

n

Homeless

31

62.0%

19

38.0%

50

SATCa

29

63.0%

17

37.0%

46

Community

1

33.3%

2

66.7%

3

Total

61

61.6%

38

38.4%

99

White

42

65.6%

22

34.4%

64

Black

17

51.5%

16

48.5%

33

Hispanic

1

100.0%

0

0.0%

1

Native American

1

100.0%

0

0.0%

1

Total

61

61.6%

38

38.4%

99

Male

49

59.0%

34

41.0%

83

Female

12

75.0%

4

25.0%

16

Total
61
SATC = substance abuse treatment centers

61.6%

38

38.4%

99

Race

Gender

a

Primary outcomes
58.6% of patients (n = 58) were seen by a PCP at a local FQHC, at an average of 60 days
after initial screening (Table 3). 65.8% of the VHC attained subgroup (n=25) were seen by a PCP
at an average of 57 days post-antibody screening, while 54.1% of the VHC eligible group were
seen by a PCP (n=33). Average time to viral RNA confirmation and ultrasound (US) were 87 days
and 89 days, respectively. For those attending one VHC appointment, average time to RNA testing
and ultrasound were 96 and 94 days, respectively. Average time from HCV screening to scheduled
VHC appointment was nearly seven months (218 days). Average time to first VHC appointment
for the 38 achieving this cascade level was 196 days from initial antibody screen, while average
time to scheduled VHC appointment was 190 days.
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Table 2. Self-reported characteristics by VHC status
VHC Eligible
n
Ave

VHC Attained
n
Ave

Total
n

Ave

p-value

Age

56

42.6

37

45.6

93

43.8

Prior access to healthcare (HC)

n

% yes

n

% yes

n

% yes

Previous HIV test

60

91.7%

36

100.0%

96

94.8%

Previous HCV test

59

78.0%

37

78.4%

96

78.1%

Previous HCV antibody +

38

92.1%

24

75.0%

62

85.5%

Previous treatment

13

30.8%

9

66.7%

22

45.5%

Insurance

26

76.9%

16

75.0%

42

76.2%

PCP

26

23.1%

16

6.3%

42

16.7%

Accessed HC previously

39

92.3%

19

78.9%

58

87.9%

Distrust

40

25.0%

19

0.0%

59

16.9%

Financial

44

59.1%

25

60.0%

69

59.4%

Drugs

41

46.3%

19

31.6%

60

41.7%

Self-reported barriers to HC access

Alcohol

39

17.9%

19

10.5%

58

15.5%

Transportation

40

42.5%

22

50.0%

62

45.2%

Incarceration

39

0.0%

20

15.0%

59

5.1%

None

48

22.9%

26

30.8%

74

25.7%

Blood splash

61

27.9%

38

47.4%

99

35.4%

Organ transplant

61

0.0%

38

0.0%

99

0.0%

Alcohol use

61

47.5%

38

55.3%

99

50.5%

Substance

61

63.9%

38

73.7%

99

67.7%

Tattoo

61

77.0%

38

84.2%

99

79.8%

Amateur tattoo

32

25.0%

18

33.3%

50

28.0%

Jail or prison

61

93.4%

38

89.5%

99

91.9%

Jail

45

86.7%

21

100.0%

66

90.9%

Prison

45

42.2%

21

47.6%

66

43.9%

Blood transfusion

61

18.0%

38

7.9%

99

14.1%

Intravenous drug use (IVDU)

61

67.2%

38

78.9%

99

71.7%

Shared injection equipment

45

46.7%

21

71.4%

66

54.5%

Diagnosed psychiatric condition

61

31.1%

38

28.9%

99

30.3%

Schizophrenia

45

4.4%

21

0.0%

66

3.0%

Depression

45

31.1%

21

19.0%

66

27.3%

Bipolar

45

13.3%

21

9.5%

66

12.1%

Anxiety

45

20.0%

21

19.0%

66

19.7%

*

*

History of
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ADHD
*p<0.05

45

2.2%

21

0.0%

66

1.5%

**p<0.01

Secondary outcomes
Pre-eligibility delays were defined as the amount of time between first VHC appointment
and being deemed eligible to apply to Medicaid for treatment. Clients completing eligibility during
their first VHC appointment (n=15), served as a baseline, with any additional days between first
VHC and being deemed eligible considered delays (Figure 1). 23 patients experienced preeligibility delays, with incomplete lab work or recent ultrasound cited as the most common reason
for deferring Medicaid application (Table 4). Positive urine drug or EtOH screen or self-reported
drug or alcohol use were the next most commonly cited reasons. Post-eligibility delays were
defined as the amount of time between being deemed eligible to apply to Medicaid for treatment
and the actual day of treatment initiation, with 21 days deemed “no delay.” Low fibrosis score was
the most commonly cited reason for application denial, delaying clients an average of 283 days
(Table 5). Insurer preferences for one medication regimen over that initially prescribed by the
provider delayed two patients by an average of 82.5 days.
Table 3. Time to various levels of care cascade (days)
VHC Eligible & Attained
n

Average
(days)

1st PCP appt

58

RNA

83

US
Scheduled VHC appt

Time to

VHC Attained

St Dev

n

Average
(days)

60

104

25

57

130

87

141.4

35

96

144.4

68

89

106.3

34

94

109.9

99

218

154.2

38

190

141.6

38

196

144

1st VHC appt

St dev

Table 4. Pre-eligibility delays by reason
Reason
Lost to follow up
Alcohol use

b

n

Completed
txa (n)

Average delay
(days)

1

1

448
126

3

1

Drug usec

6

0

Repeat lab work/US

1

0

Incomplete lab work/US

13

3

Total
24
5
Tx = treatment
b
Positive EtOH screen or self-reported alcohol use in past 6 months
c
Positive urine drugs screen (UDS) or self-reported drug use in past 6 months

110
150

a
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Table 5. Post-eligibility delays by reason
n

Completed txa
(n)

Average
delays (days)

Drug useb

2

1

453

Lost to follow up

2

0

Low fibrosis score

10

1

Repeat lab work/US

2

1

71

Insurance preferences

2

2

82.5

18

5

194.4

Reason

Total
a
b

283

Tx = treatment
Positive urine drugs screen (UDS) or self-reported drug use in past 6 months

DISCUSSION
This vulnerable population of people experiencing homelessness and undergoing substance
abuse treatment faced significant barriers to accessing HCV treatment. High attrition along the
care cascade as evidenced by less than half of eligible patients reaching a specialist, a high rate of
Medicaid DAA application denials, and significant overall time to reaching treatment initiation
were hallmarks of these patients’ experiences accessing HCV treatment. Along almost every stage
of the care cascade, patients experienced institutional and policy roadblocks that made achieving
sustained virological response (SVR) less and less likely. Given high rates of self-described
barriers to accessing healthcare reported by this population, additional regulatory restrictions are
particularly onerous for this group.
Provider restriction
Significant discrepancies in access to a PCP and specialist were found for this
disadvantaged population. Average time to see a specialist was over three times longer than that
to see a PCP. Further, those patients that were scheduled to a see a specialist sooner were more
likely to attend the appointment. Given the indigent nature of this vulnerable population, rapid
access to a provider was a key element to success along the care cascade. During the majority of
the study period, only a specialist in the fields of infectious disease, gastroenterology, or
hepatology was able to submit a DAA prior-authorization application to Medicaid (Louisiana
Department of Health, 2016). Given the high safety profile and effectiveness of DAAs, the medical
necessity of restricting dispensing power has been criticized. A number of prospective studies have
compared DAA treatment prescribed by primary care physicians and nurse-practitioners at
community-level clinics to those prescribed by specialists at academic HCV clinics. Results
revealed high rates of SVR and low rates of adverse effects in both groups (Arora et al., 2011;
Kattakuzhy et al., 2017). Given the significant attrition of this population in the time frame of
referral from PCP to specialist, it is likely that this requirement decreased access to timely,
efficacious HCV treatment.
Liver fibrosis
A low fibrosis score was the most common reason the patients in this study experienced
considerable post-eligibility delays. Medicaid’s reimbursement criteria require patients to have
advanced fibrosis/cirrhosis (Metavir stage ≥3 or Ishak stage ≥4) in order to be eligible for DAA
treatment, despite contrary recommendations from expert committees and organizations
(Louisiana Department of Health, 2016). For example, the most current AASLD/IDSA
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recommendations still support treatment with DAAs for all patients chronically infected with HCV
(genotypes 1-6) with or without cirrhosis (AASLD/IDSA, 2017). Given the many complications
of untreated chronic HCV infection including advanced liver disease, decompensated cirrhosis,
hepatocellular carcinoma (HCC), liver transplant, and death, early treatment and eradication of the
virus is crucial. Early treatment of chronic HCV infection and SVR has been shown to reduce allcause mortality (Backus et al., 2011). Prevention of liver-related diseases may not be the only
benefit with early HCV treatment. More recent studies seem to suggest that chronic HCV infection
is also linked to increased subclinical cardiovascular disease (CVD) and potentially increased
CVD outcomes (Babiker et al., 2017). More importantly, HCV treatment resulting in SVR appears
to reduce these CVD risk, raising the importance of early treatment (Babiker et al., 2017).
Additionally, in a cohort study, SVR after treatment has shown to reduce the incidence of onset of
type 2 diabetes (Arase et al., 2009).
Recent substance use
Recent alcohol or illicit drug use was a key cause of pre-eligibility delays and recent illicit
drug use caused significant post-eligibility delays in the study population. During a majority of the
study period, Medicaid required patients to remain sober from alcohol and illicit drugs for 12
months in order to be eligible for DAA treatment (Louisiana Department of Health, 2016).
However, recent studies suggest that history of alcohol abuse should not serve as a deterrent to
HCV treatment. In patients who were closely supported and monitored, history of high pretreatment alcohol consumption or failure to maintain sobriety for 6 months before treatment did
not affect treatment completion rates or SVR (Russell et al., 2012). Furthermore, a cohort study of
individuals with alcohol abuse/dependence revealed that chronic HCV infection significantly
reduces survival in this group compared to those without infection (Muga et al., 2018). This
suggests that patients with concurrent HCV infection and alcohol-abuse should be more readily
treated, rather than delaying treatment. Towards the conclusion of the study period, effective May
2018, Louisiana Medicaid made amendments to their reimbursement criteria, loosening
restrictions on providers qualified to prescribe DAAs and reducing sobriety requirements
(Louisiana Department of Health, 2018).
Limitations
A major limitation of this study is its generalizability outside the relatively isolated
healthcare system of New Orleans. These findings may not be applicable to other parts of
Louisiana, which potentially present with their own set of barriers to access. Further, low rates of
VHC eligibility and attainment resulted in a low sample size for this study despite an extensive
enrollment period. Given the complex psychosocial factors impacting this population’s decision
to pursue medical care, it is difficult to isolate delays caused by institutional and policy barriers
from social determinants. Finally, changes to Medicaid DAA policy in May 2018 may have
impacted prescribing factors in the tail end of the study. The effects of this recent policy revision
are yet unclear and further studies are needed to determine if this revision will truly make DAAs
more accessible to Medicaid patients.
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